Cascade screening is a strategy in which, after one person is diagnosed with a hereditary condition, their close biological relatives are systematically offered testing for the same genetic variant. The approach exploits a simple biological fact: first-degree relatives of someone carrying a disease-causing mutation have a much higher chance of carrying it themselves than a random person off the street. Despite that logic, cascade screening remains dramatically underused in most countries, with uptake rates that vary wildly depending on who does the contacting, what condition is involved, and whether cost or stigma stands in the way.
How It Works in Practice
The process starts with an index patient, sometimes called the proband, who receives a confirmed genetic diagnosis. A genetics professional then identifies which relatives are at risk and, through one of several methods, those relatives are invited to undergo targeted testing. Because clinicians already know the exact variant to look for, the test for each relative is faster, cheaper, and more definitive than the broad diagnostic workup the original patient went through. It is also far more efficient than screening the general population, because the prior probability of finding a carrier among close relatives is so much higher. For some conditions, cascade screening of first- through third-degree relatives can be roughly fifty times more efficient than testing the population at large.
The conditions that benefit most share a few features: the genetic variant is well characterized, there is something medically useful a carrier can do with the information, and the inheritance pattern means a meaningful fraction of relatives will also carry the variant. The three disease areas where cascade screening has the deepest evidence base are familial hypercholesterolemia, hereditary cancer syndromes, and inherited cardiovascular diseases.
Familial Hypercholesterolemia
Familial hypercholesterolemia is one of the most common serious genetic conditions, causing dangerously high LDL cholesterol from birth and putting affected people at elevated risk of premature heart disease. It follows a dominant inheritance pattern, meaning each first-degree relative of a diagnosed person has a one-in-two chance of carrying the same mutation. The UK’s National Institute for Health and Clinical Excellence specifically recommends cascade screening of close biological relatives of anyone clinically diagnosed with the condition, with the goal of identifying carriers early enough for cholesterol-lowering treatment to prevent heart attacks and death.1PubMed Central. Cascade Screening for Familial Hypercholesterolemia (FH)
The economic case is strong. An updated systematic review of screening strategies found cascade screening to be cost-effective in about three-quarters of the studies examined, with cost-effectiveness ratios ranging from the strategy actually saving money to roughly $105,000 per quality-adjusted life year gained.2PubMed Central. Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review Several countries have begun implementing national programs, and experts have argued that cascade screening for familial hypercholesterolemia should be organized at a national level, with a centralized patient registry to track diagnoses and coordinate outreach to families.3PubMed. Cascade screening for familial hypercholesterolemia should be organized at a national level Germany’s CaRe High project, for example, combines a patient registry with systematic cascade testing to improve detection and treatment rates.4PubMed. CaRe high – Cascade screening and registry for high cholesterol in Germany
Hereditary Cancer Syndromes
BRCA1 and BRCA2 mutations substantially raise the risk of breast, ovarian, and other cancers, and Lynch syndrome mutations increase the risk of colorectal, endometrial, and several additional cancers. For both, cascade testing of relatives is considered critically important. In Lynch syndrome, the cost-effectiveness of universal tumor screening in colorectal cancer patients depends entirely on whether the at-risk relatives identified through that screening actually go on to get counseling and tested themselves, because it is the young, unaffected carriers who stand to benefit most from early surveillance and prevention.5PubMed. Genetic counseling and cascade genetic testing in Lynch syndrome
Relatives found to carry BRCA1/2 mutations are typically offered cancer risk-reducing strategies, which can include increased surveillance, preventive medications, or risk-reducing surgery based on established clinical guidelines.6PubMed Central. Facilitated cascade testing (FaCT): a randomized controlled trial The actionability of the results is a genuine motivator: a qualitative study of male relatives of BRCA carriers found that knowing test results could lead to concrete preventive steps was one of the key factors encouraging men to get tested.7PubMed Central. A Multi-Level Analysis of Barriers and Promoting Factors to Cascade Screening Uptake Among Male Relatives of BRCA1/2 Carriers: A Qualitative Study
Inherited Heart Conditions
Inherited cardiovascular diseases, including hypertrophic cardiomyopathy, dilated cardiomyopathy, and long QT syndrome, affect an estimated one to two percent of the global population. Cascade genetic counseling and testing are considered especially valuable here because preventive measures and treatments exist for many of these conditions.8PubMed Central. Cascade genetic counseling and testing in hereditary syndromes: inherited cardiovascular disease as a model: a narrative review The stakes can be high: hypertrophic cardiomyopathy and long QT syndrome are both linked to sudden cardiac death, and identifying carriers before a cardiac event allows for medication, lifestyle modifications, or device implantation that can be lifesaving.
In a study of pediatric patients with long QT syndrome and hypertrophic cardiomyopathy, about three-quarters of families accepted cascade screening. Among the relatives who were tested, roughly four in ten turned out to be positive, with an average of just under one new case detected per family.9PubMed. Genetic testing and cascade screening in pediatric long QT syndrome and hypertrophic cardiomyopathy Those are meaningful detection rates that translate directly into preventive care for people who otherwise might not have known they were at risk.
Who Contacts the Relatives, and Why It Matters
One of the biggest practical variables in cascade screening is notification method. In most systems, the diagnosed patient is simply asked to tell their family members about the result and encourage them to get tested. This sounds reasonable but performs poorly. A scoping review found that when patients were responsible for contacting relatives, genetic testing uptake for familial hypercholesterolemia was only about 23 percent, and only about half of relatives were even made aware of a BRCA1/2 mutation in their family.10Health Affairs. Delivery Of Cascade Screening For Hereditary Conditions: A Scoping Review Of The Literature
When healthcare providers get more directly involved, the numbers improve dramatically. The same review found that in programs where a genetics specialist was added to the care team, the number of relatives tested per patient jumped from about 0.13 to over one. In one program that actively reached out to first-degree relatives, about 81 percent of contacted relatives either completed testing or were already known to be affected.11Health Affairs. Delivery Of Cascade Screening For Hereditary Conditions: A Scoping Review Of The Literature This enormous gap between patient-driven and provider-driven outreach is one of the clearest and most consistent findings in the cascade screening literature.
A survey-based study found that health system-led direct contact of relatives is acceptable to patients and families in the United States, as long as it follows a programmatic approach, includes consent of relatives before the proband’s testing, and complements rather than replaces the patient’s own communication with their family.12PubMed Central. Patient and Family Preferences on Health System-Led Direct Contact for Cascade Screening In other words, families generally welcome professional involvement as long as they retain some control over how information flows.
Why Relatives Do Not Get Tested
Even when relatives are aware of a familial risk, many never follow through with testing. The barriers fall into several categories. At the individual level, fear of a positive result is the most commonly reported obstacle. In one study that followed up with at-risk relatives who had been sent free at-home saliva test kits but never returned them, nearly half cited fear of what the results might show. Others mentioned concern about genetic discrimination or a belief that the mutation was not relevant to their own health.13PubMed Central. Barriers to completion of cascade genetic testing: How can we improve the uptake of testing for hereditary breast and ovarian cancer syndrome?
A broader scoping review organized the psychosocial landscape into facilitators, barriers, and factors that can cut either way depending on the family. Facilitators include a belief in health protection, family closeness, and support from health professionals. The clearest barrier is negative family dynamics, where strained relationships or hostile reactions to the news prevent information from flowing at all. Then there are bidirectional factors like negative emotions and perception of genetic risk, which in some families drive people toward testing and in others push them away.14PubMed. Psychosocial barriers and facilitators for cascade genetic testing in hereditary breast and ovarian cancer: a scoping review
At the system level, prohibitive costs, fragmented referral pathways, shortages of genetics professionals, and legal gaps around genetic discrimination all reduce uptake.15PubMed. Cascade Testing Barriers: How to Overcome? In the United States, the Genetic Information Nondiscrimination Act (GINA) prohibits genetic discrimination in health insurance and employment, but it does not cover life insurance, disability insurance, or long-term care insurance. That gap is not theoretical: concern about genetic discrimination was specifically cited by at-risk relatives as a reason for declining testing.16PubMed Central. Barriers to completion of cascade genetic testing: How can we improve the uptake of testing for hereditary breast and ovarian cancer syndrome?
Racial and Ethnic Disparities
Cascade testing rates are low across the board, but they are especially low among Black and other minority families. A large study of families with cancer predisposition genes found that significantly fewer Black probands had at least one relative undergo cascade testing compared with White probands, with rates of roughly 12 percent versus 22 percent. This disparity persisted even after the institution introduced a no-charge testing policy, suggesting that cost alone does not explain the gap.17PubMed. Racial disparities in cascade testing for cancer predisposition genes
A separate large analysis confirmed these patterns, finding that non-Hispanic White individuals were most likely to have at least one relative pursue cascade testing, at about 27 percent. African American or Black families had rates around 16 percent, and Middle Eastern families had the lowest observed rates at roughly 12 percent.18JAMA Network Open. Differences in Cascade Genetic Testing Among Families With Hereditary Cancer Risk The reasons behind these disparities are not fully understood but likely involve a combination of historical medical distrust, differences in access to genetics services, cultural variation in family communication norms, and structural inequities in healthcare delivery.
Digital Tools for Closing the Gap
One promising approach to improving cascade testing uptake is using digital tools that reduce the burden on both patients and providers. Several research teams have developed chatbot-based systems that patients can share electronically with relatives. The chatbot explains the genetic finding, describes associated health risks, and guides the relative toward scheduling a genetics appointment.
In one implementation, almost all patients offered a cascade chatbot accepted it. By three months, about 83 percent of those patients had shared the chatbot with at least one relative, and a total of 122 relatives received it. Among those relatives, roughly half scheduled or completed a genetics appointment as a direct result of the chatbot, and of those who completed an appointment, about 86 percent went through with genetic testing.19PubMed Central. Cascade chatbot: A scalable approach to family-based genetic testing for hereditary cancer syndromes A related study using a Family Sharing Tool found that cascade genetic testing uptake was significantly greater among relatives of patients who used the digital tool compared with those who declined it.20PubMed. Use of a chatbot to increase uptake of cascade genetic testing
An online platform called PROACT reported that among confirmed eligible relatives who accessed the tool, about two-thirds ordered testing. When measured against all presumptively eligible relatives in the families, the overall yield was about 17 percent, which is modest but represents relatives who might not have been reached at all through traditional methods.21Journal of Clinical Oncology. Clinical implementation of an online family cascade genetic testing platform: The Preventive Risk Outreach and Cascade Testing (PROACT) initiative These tools do not replace genetic counseling, but they lower the activation energy for that first step of reaching out to family members, which is precisely where the process most often stalls.
The Ethics of Warning Relatives
Cascade screening creates an unusual ethical tension. A physician who identifies a serious hereditary risk in a patient knows that the patient’s relatives may also be at risk. If the patient refuses to share that information, the physician is caught between respecting patient confidentiality and the potential to prevent serious harm in another person.22PubMed. Duty to warn at-risk relatives for genetic disease: genetic counselors’ clinical experience
This is not a hypothetical dilemma. A New Jersey appellate court ruled in the case of Safer v. Estate of Pack that a physician has a duty to warn those known to be at risk of a genetic disorder, and that this duty may not always be satisfied simply by telling the patient. The court acknowledged this could conflict with the patient’s explicit preference for privacy, a principle that has been foundational to medical ethics for centuries.23Genetics in Medicine. Reconsidering the duty to warn genetically at-risk relatives The legal landscape remains unsettled. Most jurisdictions have not clearly defined whether the duty to warn extends to a patient’s genetic relatives, and the ethical debate among geneticists and counselors is ongoing.24JAMA. The “Duty to Warn” a Patient’s Family Members About Hereditary Disease Risks
Emotional Impact on Relatives
A common concern is whether approaching people out of the blue with news that they might carry a disease-causing mutation causes lasting psychological harm. The evidence suggests it generally does not, though the picture has some nuance. In one study of a familial hypercholesterolemia screening program, about 20 percent of people who were contacted reported feeling some social pressure, but effects on mood and quality of life were minimal to absent.25Community Genetics. How Disturbing Is It to Be Approached for a Genetic Cascade Screening Programme for Familial Hypercholesterolaemia?: Psychological Impact and Screenees’ Views
Among unaffected relatives who underwent cascade testing with multigene panel testing for hereditary cancer, only about 6.5 percent reached the threshold for high psychological distress after receiving their results. Those who tested positive for a disease-causing variant had higher average distress scores than those who tested negative, but the differences were not statistically significant after adjusting for other factors. The strongest predictor of distress after getting results was not the result itself but how worried the person was about cancer before they were ever tested.26Journal of Human Genetics. Psychological distress and cancer worry in unaffected relatives undergoing cascade testing with multigene panel testing This suggests that screening programs might benefit from identifying and supporting high-anxiety individuals before results are disclosed, rather than assuming the test result is the primary source of distress.
Testing Children and Adolescents
Cascade screening raises particular questions when the at-risk relative is a child. For conditions where early intervention changes outcomes, such as familial hypercholesterolemia or long QT syndrome, pediatric testing is generally supported because treatment can begin in childhood. The pediatric cardiac data mentioned earlier, with a 75 percent family acceptance rate, reflects this: parents tend to be willing to test their children for conditions where knowing early can prevent serious harm.27PubMed. Genetic testing and cascade screening in pediatric long QT syndrome and hypertrophic cardiomyopathy
For adult-onset conditions where no childhood intervention exists, however, the European Society of Human Genetics recommends a more cautious approach. Pre-symptomatic testing for conditions like Lynch syndrome and BRCA-related hereditary cancer should generally be postponed until children reach the age of competence and can make autonomous decisions for themselves. The concern is that as genetic testing has become more routine, children may be tested without adequate consideration of whether knowing serves their interests at that stage of life.28European Journal of Human Genetics. Cascade counselling and testing. Recommendations of the European Society of Human Genetics
When Variants Are Uncertain
Not every genetic finding is a clear positive or negative. Some results come back as a variant of uncertain significance, meaning the lab has found a change in the gene but does not yet know whether it causes disease. This creates a practical problem for cascade screening: should you test relatives for a variant you cannot yet interpret? The answer, in many cases, is to wait and revisit. A study of patients with cardiomyopathy found that periodic re-evaluation of uncertain variants led to reclassifications that changed clinical management for some patients and their families. The authors recommended re-evaluating uncertain results every three to five years as scientific knowledge evolves.29Journal of Medical Genetics. Reassessment and reclassification of variants of unknown significance in patients with cardiomyopathy in a specialist department For families sitting in that uncertain zone, the practical takeaway is to stay connected with a genetics clinic that will revisit the result as evidence accumulates.
Unexpected Discoveries in the Family Tree
Cascade genetic testing occasionally reveals information that no one was looking for. One of the more sensitive possibilities is the discovery of misattributed parentage, where testing reveals that a presumed biological relationship does not exist. The most common form involves non-paternity. This can surface during cascade testing when a relative’s results are unexpectedly inconsistent with the known family variant, or during family studies meant to clarify an uncertain result.30IntechOpen. Practical Aspects of Cardiovascular Genetic Counseling There is no consensus in the genetics community on whether and how to disclose such findings, and the consequences for families can be significant. Genetic counselors are trained to handle these situations, but it is worth knowing that cascade testing can occasionally open doors that were not part of the original question.
Recessive Conditions and the Limits of Cascade Screening
Cascade screening works best for dominant conditions where carrying one copy of a variant is enough to cause disease or substantially raise risk. For recessive conditions, where a person needs two copies to be affected, the calculus shifts. Modeling work has shown that for a rare recessive disorder like cystic fibrosis, testing all siblings and first cousins of known carriers would require reaching less than two percent of the population but would detect only about 15 percent of new cases. For rarer conditions the yield is even worse.31PubMed. Is cascade testing a sensible method of screening a population for autosomal recessive disorders? The efficiency advantage over population screening remains, but the detection rate is too low for cascade screening alone to serve as a meaningful public health strategy for most recessive diseases.
There are exceptions. For relatively common recessive conditions with reduced penetrance, such as hereditary hemochromatosis, cascade screening of first- through third-degree relatives can identify up to 40 percent of at-risk individuals, with an efficiency roughly fifty times higher than population-wide screening.32PubMed Central. Estimating the efficacy and efficiency of cascade genetic screening The general principle is that cascade screening’s value tracks closely with how common the variant is and how strongly the inheritance pattern concentrates risk within families.